Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Institute of Liver and Biliary Sciences, India
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07465471CT.gov Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. | — | Not Yet Recruiting | — | — | — |
NCT06245590CT.gov Evaluation of Low-dose Albumin and Midodrine Versus Midodrine Alone in Outcome of Recurrent Ascites in Patients With Decompensated Cirrhosis. | — | Unknown | — | — | — |
NCT06091345CT.gov Midodrine Plus Albumin Versus Midodrine Alone to Prevent Cirrhosis Related Complications in Children With Cirrhosis and Ascites | — | Completed | — | — | — |
NCT05287100CT.gov To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation. | — | Completed | — | — | — |
NCT05084534CT.gov Efficacy and Safety of Midodrine in Refractory or Recurrent Ascites in Children With Cirrhosis. | — | Withdrawn | — | — | — |
NCT05060523CT.gov To Study Effect of the Combination of Midodrine and Tolvaptan Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis(TOLMINA Trial) | — | Unknown | — | — | — |
NCT04048707CT.gov Angiotensin 2 for Hepatorenal Syndrome | — | Withdrawn | — | — | — |
NCT04816240CT.gov Evaluation of Albumin and Midodrine Versus Albumin Alone in Outcome of Refractory Ascites in Patients With Decompensated Cirrhosis. | — | Unknown | — | — | — |
NCT04208776CT.gov Efficacy of Combination of Midodrine With Propranolol in Preventing First Bleed in Decompensated Cirrhotics With Severe Ascites. | — | Completed | — | — | — |
NCT03144713CT.gov Efficacy and Safety of Terlipressin With Albumin Versus Midodrine With Albumin Versus Albumin Alone in Prevention of Paracentesis Induced Circulatory Dysfunction in Cirrhosis | — | Completed | — | — | — |
Show 4 more trialsShow fewer
NCT02173288CT.gov Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites | — | Completed | — | — | — |
NCT01331785CT.gov Mechanism and the Effect of Midodrine on Portal Pressures in Patients With Cirrhosis | — | Withdrawn | — | — | — |
NCT01133795CT.gov Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment | — | Completed | — | — | — |
NCT00108355CT.gov Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cirrhosis Of Liver
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Midodrine (this asset) | Institute of Liver and Biliary Sciences, India | Approved | BB · 66 |
| Veruprevir | AbbVie | P3 | A |
| Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) | General Hospital of Shenyang Military Region | P4 | BBB |
| Tolvaptan | Institute of Liver and Biliary Sciences, India | P4 | BBB |
| Ribavirin | Peking University People's Hospital | P4 | BBB |
| Cholyl-Lysl-Fluorescein | Norgine | P3 | BBB |
| Normal Human Serum Albumin | King George's Medical University | P4 | BBB |
| Ombitasvir | AbbVie | P3 | BBB |
| Colchicinum | Beth Israel Deaconess Medical Center | P4 | BBB |
+42 more in the Cirrhosis Of Liver cohort
Other indications for Midodrine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Quadriplegia | — | P4 | BB · 71 |
| Spontaneous Periodic Hypothermia | — | P4 | BB · 71 |
| Kidney Failure | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Midodrine in Cirrhosis Of Liver. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/midodrine-cirrhosis-of-liver
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →